ViiV Healthcare's Rukobia (fostemsavir) Receives Marketing Authorization for the Treatment of Adults with Multidrug-Resistant HIV
Shots:
- The MAA is based on P-III BRIGHTE study assessing Rukobia (600mg- bid) + OBT vs PBO in 371 HTE adults living with multidrug-resistant HIV. Participants were enrolled in either a randomized or nonrandomized cohort
- In the randomized cohort- 60% achieved undetectable HIV viral load and clinically meaningful improvements to CD4+ T-cell count @96wks.- HIV-1 RNA <40 copies/mL @24 & 96wks. (53% & 60%); changes in CD4+ cell count (90 & 205 cells/mm3)
- In the nonrandomized cohort- 37% achieved HIV-1 RNA <40 copies/mL @24 & 96wks.; HIV-1 RNA <200 copies/mL (42% & 39%); mean changes in CD4+ cell count (41 & 119 cells/mm3) respectively. Fostemsavir is a 1st in class HIV-1 attachment inhibitor
Ref: ViiV Healthcare | Image: ViiV Healthcare
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com